CervoMed (CRVO) Cash & Equivalents (2010 - 2026)

CervoMed has reported Cash & Equivalents for 17 years, with the latest figure at $7.9 million in Q1 2026.

• Quarterly Cash & Equivalents fell 24.38% year-over-year to $7.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.9 million (down 24.38% YoY) and the FY2025 annual result came in at $8.2 million, down 8.49% from the prior year.
• Cash & Equivalents eased to $7.9 million in Q1 2026 per CRVO's latest filing, from $8.2 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $15.0 million in Q2 2023 and troughed at $4.1 million in Q4 2022.
• A 5-year average of $8.9 million and a median of $8.3 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents slumped 89.03% in 2022, then jumped 151.43% in 2023.
• Over 5 years, Cash & Equivalents stood at $4.1 million in 2022, then surged by 90.37% to $7.8 million in 2023, then advanced by 15.48% to $9.0 million in 2024, then fell by 8.49% to $8.2 million in 2025, then retreated by 3.57% to $7.9 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $7.9 million, $8.2 million, and $9.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.